

Procalcitonin as an indicator of urosepsis

Koichi Sugimoto
Shogo Adomi
Hiroyuki Koike
Atsunobu Esa

Department of Urology, NTT West
Osaka Hospital, Osaka, Japan

Background: Procalcitonin has been advocated as a marker of bacterial infection, so this study was carried out to determine the usefulness of serum procalcitonin in the early diagnosis of urosepsis.

Methods: The subjects were 37 febrile patients with urinary tract infection in whom we examined the serum procalcitonin concentration at the start of treatment.

Results: Thirty patients had acute pyelonephritis (16 simple, 14 complex), one had emphysematous pyelonephritis, five had acute prostatitis, and one had acute epididymitis. The procalcitonin level was <0.5 ng/mL in 18 patients, ≥ 0.5 ng/mL in one patient, ≥ 2 ng/mL in seven patients, and ≥ 10 ng/mL in 11 patients. Five of the 11 patients with procalcitonin levels ≥ 10 ng/mL had disseminated intravascular coagulation. All patients with urinary tract obstruction and disseminated intravascular coagulation had procalcitonin levels ≥ 10 ng/mL.

Conclusion: Although this retrospective study comprised a small number of patients, we found that procalcitonin was a useful marker for urinary tract infection.

Keywords: procalcitonin, urosepsis, urinary tract infection, urology

Introduction

Blood culture is a very specific method for detection and confirmation of septicemia, but test results are available only after 24 hours. C-reactive protein is an acute-phase protein produced by the liver in response to tissue injury or infection. However, the C-reactive protein level can also be very high in nonseptic states, eg, postoperatively and in inflammatory disease.^{1,2} However, a definite correlation between infection and changes in C-reactive protein has not been documented as yet.

Procalcitonin is a 13 kDa, 116-amino acid prohormone of calcitonin. In 1993, Assicot et al³ reported increased procalcitonin levels in patients with sepsis and infection. Further clinical studies indicated that bacterial inflammation and sepsis, but not viral infections or autoimmune disorders, could induce high concentrations of serum procalcitonin.³⁻⁷ In this study, we evaluated the relationship between urosepsis and procalcitonin.

Materials and methods

From January 2008 to October 2010, 37 patients with febrile urinary tract infection (UTI) had their procalcitonin levels measured and were evaluated for the severity of UTI at our hospital. Our criteria for UTI were febrile symptoms (ie, dysuria, low back pain) and a core body temperature more than 38°C.

Correspondence: Koichi Sugimoto
Department of Urology, NTT West
Osaka Hospital, 2-6-40, Karasugatsuji,
Tennoji, Osaka, 543-8922, Japan
Email sugimoto@sakai.med.kindai.ac.jp

All patients provided a urine sample for culture before treatment with antibiotics. If patients needed to be hospitalized, blood culture was performed at least twice before administration of antibiotics. Blood culture was confirmed to be positive if the same organism was found in urine culture.

The BRAHMS PCT-Q (Thermo Fisher Scientific, Waltham, MA, USA) is an immunochromatographic test for semiquantitative detection of procalcitonin, and is used for diagnosing and monitoring the effects of treatment for severe bacterial infection and sepsis. The BRAHMS PCT-Q test system requires an incubation period of only 30 minutes, is not apparatus-dependent, and does not need calibrating. The test uses a monoclonal mouse anticatalcalcin antibody conjugated with colloidal gold and a polyclonal sheep calcitonin antibody.

A procalcitonin level < 0.5 ng/mL indicates the possibility of local bacterial infection; ≥ 0.5 ng/mL indicates that a systemic infection (sepsis) is unlikely; ≥ 2 ng/mL suggests the possibility of a systemic infection (sepsis), although various other conditions are also known to induce procalcitonin; and ≥ 10 ng/mL indicates the likelihood of sepsis, unless other causes for a high procalcitonin level are known. It is important to note that a systemic inflammatory response is almost exclusively due to severe bacterial sepsis or septic shock.⁸

Comparisons between groups were performed using the Mann–Whitney *U* test and Kruskal–Wallis nonparametric analysis of variance.

Results

Thirty patients had acute pyelonephritis (16 without and 14 with resistant-organ acute pyelonephritis), one had emphysematous pyelonephritis, five had acute prostatitis, and one patient had acute epididymitis. The procalcitonin level was < 0.5 ng/mL in 18 patients, ≥ 0.5 ng/mL in one patient, ≥ 2 ng/mL in seven patients, and ≥ 10 ng/mL in 11 patients.

All patients had positive urine cultures. The principal bacterium was *Escherichia coli* (Table 1). As shown in Table 2, 16 of 20 patients had a positive blood culture, and the procalcitonin level was < 0.5 ng/mL in 2/5 patients (40%), ≥ 2 ng/mL in 6/6 patients (100%), and ≥ 10 ng/mL in 8/9 patients (88.9%). There was only one patient with procalcitonin ≥ 0.5 ng/mL, so we excluded this case from the statistical analysis.

No significant differences were observed between procalcitonin and C-reactive proteins levels or between

Table 1 Results of urine culture

Bacteria	Number
<i>Escherichia coli</i>	18
<i>Enterococcus faecalis</i>	4
<i>Pseudomonas aeruginosa</i>	2
<i>Klebsiella oxytoca</i>	2
<i>Klebsiella pneumoniae</i>	2
<i>Enterobacter cloacae</i>	2
Methicillin-resistant <i>Staphylococcus aureus</i>	2
<i>Staphylococcus aureus</i>	2
<i>Proteus mirabilis</i>	1
<i>Acinetobacter lwoffii</i>	1
<i>Escherichia coli</i> , ESBL-producing	1

procalcitonin and white blood cell levels. Eleven patients had procalcitonin levels ≥ 10 ng/mL. Eight of these patients required drainage and five had disseminated intravascular coagulation. All patients with urinary tract obstruction and disseminated intravascular coagulation had procalcitonin levels ≥ 10 ng/mL (Table 3).

Discussion

UTI is a disease commonly encountered in the clinical setting, and sepsis resulting from UTI is a serious condition that can affect the prognosis. It has been reported that the mortality rate due to urosepsis is 16.1%.⁹ It has also been reported that 78% of cases of urosepsis are due to urinary tract obstruction.¹⁰

C-reactive protein is generally regarded as a useful marker for the diagnosis of sepsis and is used along with blood culture. However, such methods are sometimes inadequate for diagnosing sepsis, and a testing method enabling more rapid and efficient diagnosis has long been considered necessary.

Procalcitonin is considered a useful marker for rapid differential diagnosis of bacterial sepsis and evaluation of its severity.^{11–13} In a report comparing blood culture and procalcitonin, diagnostic sensitivity was 42.6% for blood culture and 70.2% for procalcitonin, and the diagnostic accuracy of procalcitonin calculated from its sensitivity and specificity was 75.4%.¹¹ In this study, the sensitivity and

Table 2 Relationship between procalcitonin levels and positive blood culture rate

PCT levels	Total number	Number of blood culture-positive	Rate
PCT < 0.5 ng/mL	5	2	40%
PCT ≥ 0.5 ng/mL	–	–	–
PCT ≥ 2 ng/mL	6	6	100%
PCT ≥ 10 ng/mL	9	8	88.9%

Table 3 Patients with procalcitonin levels ≥ 10 ng/mL

	Age	Sex	Disease	Stone	Drainage	DM ^h	Steroid	DIC
Case 1	72	F ^a	APN ^c	(+)	(-)	(-)	(+)	(-)
Case 2	63	F	APN	(+)	D-J ^e	(-)	(-)	(+)
Case 3	75	F	APN	(+)	D-J	(+)	(-)	(+)
Case 4	80	F	APN	(+)	PNS ^f	(+)	(-)	(+)
Case 5	73	F	APN	(+)	D-J	(-)	(+)	(-)
Case 6	37	F	APN	(+)	D-J	(-)	(+)	(+)
Case 7	58	F	EPN ^d	(-)	NpX ^g	(-)	(-)	(-)
Case 8	66	F	APN	(-)	(-)	(+)	(+)	(-)
Case 9	66	F	APN	(+)	D-J	(+)	(-)	(+)
Case 10	38	F	APN	(+)	D-J	(+)	(-)	(-)
Case 11	92	M ^b	APN	(+)	(-)	(-)	(-)	(-)

Notes: ^aFemale; ^bmale; ^cacute pyelonephritis; ^demphysematous pyelonephritis; ^eDouble J catheter; ^fpercutaneous nephrostomy; ^gnephrectomy; ^hdiabetes mellitus.

specificity calculated for procalcitonin was 78%, indicating very high diagnostic efficiency.

The recommended treatment for urosepsis is drainage of the obstructed urinary tract to secure its patency and removal of an infected lesion if present. Any delay in appropriate treatment can be fatal. The results of this study show that all 11 patients with a procalcitonin level ≥ 10 ng/mL had severe bacterial urosepsis. Of these patients, five also had disseminated intravascular coagulation and eight needed relief of an obstructed urinary tract.

With regard to pathogenic micro-organisms, others have found no significant difference in procalcitonin levels between Gram-positive cocci and Gram-negative rods.^{11,13} Similar results were noted in our patients.

The superior usefulness of procalcitonin levels in the diagnosis of sepsis in comparison with C-reactive protein has been previously reported.^{14,15} Our findings further confirm that the procalcitonin level is a useful parameter on which to base a treatment strategy because it allows prompt diagnosis of urosepsis without the need to wait for the results of blood culture. Consequently, procalcitonin should be used as an adjunctive marker to aid in the diagnosis.

Disclosure

The authors report no conflicts of interest in this work.

References

- Oberhofer D, Juras J, Pavicic AM, Rancic Z, Rumenjak V. Comparison of C-reactive protein and procalcitonin as predictors of postoperative infectious complications after elective colorectal surgery. *Croat Med J*. 2012;53(6):612–619.
- Ludwig M, Kummel C, Schroeder-Printzen I, Ringert RH, Weidner W. Evaluation of seminal plasma parameters in patients with chronic prostatitis or leukocytospermia. *Andrologia*. 1998;30 Suppl 1:41–47.
- Assicot M, Gendrel D, Carsin H, et al. High serum procalcitonin concentrations in patients with sepsis and infection. *Lancet*. 1993;341(8844):515–518.
- Gendrel D, Raymond J, Coste J, et al. Comparison of procalcitonin with C-reactive protein, interleukin 6 and interferon-alpha for differentiation of bacterial vs viral infections. *Pediatr Infect Dis*. 1999;18(10):875–881.
- Deleaux I, Andre M, Colombier M, et al. Can procalcitonin measurement help in differentiating between bacterial infection and other kinds of inflammatory processes? *Ann Rheum Dis*. 2003;62(4):337–340.
- Gendrel D, Bohuon C. Procalcitonin in pediatrics for differentiation of bacterial and viral infections. *Intensive Care Med*. 2000;Suppl 2: S178–S181.
- Ugarte H, Silva E, Mercan D, De Mendonca A, Vincent JL. Procalcitonin used as a marker of infection in the intensive care unit. *Crit Care Med*. 1999;27(3):498–504.
- Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. *Chest*. 1992;101(6):1644–1655.
- Ackermann RJ, Monroe PW. Bacteremic urinary tract infection in older people. *J Am Geriatr Soc*. 1996;44(8):927–933.
- Wagenlehner FM, Pilatz A, Naber KG, Weider W. Therapeutic challenges of urosepsis. *Eur J Clin Invest*. 2008;38 Suppl 2:45–49.
- Aikawa N, Fujishima S, Endo S, et al. Multicenter prospective study of procalcitonin as an indicator of sepsis. *J Infect Chemother*. 2005;11(3):152–159.
- Muller B, Becker KL, Schachinger H, et al. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. *Crit Care Med*. 2000;28(4):977–983.
- Yukioka H, Yoshida G, Kurita S, Kato N. Plasma procalcitonin in sepsis and organ failure. *Ann Acad Med Singapore*. 2001;30(5):528–531.
- Tang BM, Eslick GD, Craig JC, McLean AS. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. *Lancet Infect Dis*. 2007;7(3):210–217.
- Uzzan B, Cohen R, Nicolas P, et al. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. *Crit Care Med*. 2006;34(7):1996–2003.

Research and Reports in Urology**Dovepress****Publish your work in this journal**

Research and Reports in Urology is an international, peer-reviewed, open access journal publishing original research, reports, editorials, reviews and commentaries on all aspects of adult and pediatric urology in the clinic and laboratory including the following topics: Pathology, pathophysiology of urological disease; Investigation and treatment of

urological disease; Pharmacology of drugs used for the treatment of urological disease. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/research-and-reports-in-urology-journal>